Abstract Mazdutide (Xinermei ) is a dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Eli Lilly and Company along with Innovent Biologics for use in weight management in adults with obesity or overweight and for the treatment of type 2 diabetes (T2D)
avoiding high-fat foods), anti-nausea medications, or adjusting timing of administration Temporarily holding the dose : In cases of severe gastrointestinal symptoms or dehydration, a brief treatment pause may be appropriate Reviewing administration technique : For Rybelsus, ensuring strict adherence to the fasting window (4 oz water, 30 minute wait) before considering dose changes For patients with diabetes, dose adjustments must also consider glycemic control
Favor a balanced diet with sufficient lean protein, whole grains, fruits, vegetables, and healthy fats
Many patients who have plateaued on other medications or those who are looking for the best possible results find Tirzepatide to be particularly effective